Europe - Euronext Amsterdam - AMS:PHARM - NL0010391025 - Common Stock
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | 14.71M | -8.51M | -12.01M | 14.99M | 23.08M | |||
| Depreciation Amortization | 15.64M | 16.00M | 16.00M | 13.19M | 19.61M | |||
| Change In Working Capital | 330.00K | -20.00M | -15.00M | -1.54M | -4.91M | |||
| Interest Paid | 6.13M | 5.60M | 4.05M | 3.95M | 4.45M | |||
| Taxes Paid | 7.47M | 16.00M | 660.00K | 1.24M | 0.00 | |||
| Other non cash items | 23.63M | 11.00M | -6.48M | -4.18M | 62.00K | |||
| OPERATING CASH FLOW | 53.20M | -1.80M | -17.00M | 22.46M | 37.84M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -630.00K | -800.00K | -1.46M | -1.98M | -16.72M | |||
| Other Investing Activity | 17.00M | 32.00M | -128.00M | 7.30M | -4.59M | |||
| INVESTING CASH FLOW | 17.00M | 32.00M | -129.00M | 5.32M | -21.30M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | -3.88M | -34.00M | -5.13M | -3.31M | -3.22M | |||
| Stock Issued/Repurchased | 17.09M | 5.58M | 8.13M | 2.28M | 4.72M | |||
| Other Financing Activity | -13.78M | -5.60M | -4.05M | -3.95M | -29.45M | |||
| FINANCING CASH FLOW | -1.54M | -34.00M | -1.04M | -4.98M | -27.95M | |||
| Exchange Rate Effect | 3.61M | -2.21M | 2.13M | -7.38M | -1.82M | |||
| CHANGE IN CASH | 72.27M | -6.01M | -144.91M | 15.42M | -13.23M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | 53.20M | -1.80M | -17.00M | 22.46M | 37.84M | |||
| Capital Expenditure | -630.00K | -800.00K | -1.46M | -1.98M | -16.72M | |||
| FREE CASH FLOW | 52.57M | -2.60M | -18.46M | 20.48M | 21.13M | |||
All data in USD